AssetMark’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
Other funds holding SMMT
AssetMark's SMMT Position: Q3 2026 in Review
AssetMark opened a new position in Summit Therapeutics (SMMT) in Q3 2026: 8 shares worth $135. The stake represents ﹤0.01% of the portfolio and ranks #3665 among its holdings. This is a return to the name: AssetMark previously reported a position in SMMT as recently as Q4 2025.
AssetMark first reported a position in SMMT in Q2 2025 and has held it in 4 quarters since. The position peaked at $661K in Q2 2025. 211 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.
- AssetMark held 8 shares of Summit Therapeutics worth $135 as of Q3 2026.
- Summit Therapeutics was a new AssetMark position in Q3 2026.
- Summit Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3665 holding.
- AssetMark first reported a position in Summit Therapeutics in Q2 2025 and has held it in 4 quarters since.
- AssetMark's Summit Therapeutics position peaked at $661K in Q2 2025.
- 211 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.